SCHEMBL4883491

SCHEMBL4883491

c1csc(-c2ccc(C3CC4CCC(C3)N4)nc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2E1 P05181 1/20 0.37
CYP2A6 P11509 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2B6 P20813 1/20 0.37
NOTUM Q6P988 2/20 0.37
MAP3K12 Q12852 1/20 0.37
CHRNB2 P17787 3/20 0.35
CHRNA3 P32297 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HSD17B10 Q99714 2/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
ALOX15 P16050 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4876561 0.82 RAB9A (0.45) ALDH1A1HSD17B10MEN1KMT2ATDP1
SCHEMBL5242333 0.82 CHRNB2 (0.35) GRIN1GRIN2BCYP3A4CYP2E1CYP2A6
SCHEMBL4884268 0.78 OPRM1 (0.43) GRIN1GRIN2BCYP3A4CYP2E1CYP2A6
SCHEMBL4877165 0.78 CYP2A6 (0.49) CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL10722395 0.77 NOTUM (0.41) GRIN1GRIN2BCYP3A4CYP2E1CYP2A6
SCHEMBL5242339 0.74 CHRM2 (0.36) GRIN1GRIN2BCYP3A4CYP2E1CYP2A6
SCHEMBL10721754 0.72 GRIN1 (0.40) GRIN1GRIN2BCYP3A4CYP2E1CYP2A6
SCHEMBL10721760 0.72 GRIN1 (0.40) GRIN1GRIN2BCYP3A4CYP2E1CYP2A6
SCHEMBL13917342 0.69 CYP2C9 (0.53) CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL10723822 0.69 GAA (0.40) GRIN1GRIN2BCYP2C9NOTUMCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080153806-A1 Novel Diazabicyclic Aryl Derivatives And Their Medical Use NEUROSEARCH A/S (DK) 2008-06-26 US claimed
US-20080153806-A1 Novel Diazabicyclic Aryl Derivatives And Their Medical Use NEUROSEARCH A/S (DK) 2008-06-26 US disclosed
EP-1805183-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2007-07-11 EP disclosed
WO-2006045716-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153806-A1 Novel Diazabicyclic Aryl Derivatives And Their Medical Use CHRNA6, CHRNA10, CHRNA2 GRIN1 412/4885GRIN2B 188/4885CYP3A4 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.